The scientific aims are to
Scientific need: PRISAR2 is to implement a paradigm change for a novel approach in deciding if cancer surgery is needed. Therefore, our aim will be to clinically translate innovative new monitoring technologies from the industry. This will provide better patient selection and increase the surveillance window to allow for better treatment options over time and avoid surgery. This will involve developing new watch and wait strategies to study the behaviour of the cancer so that any risks can be minimised. This would lead to a better clinical outcome and quality of life (QOL) for the patient and maximise the benefits of an active monitoring policy for both the patient and the healthcare system.
- Better understand the importance of watch and wait and to estimate the risks to either perform or not to perform cancer surgery;
- Address how the implementation of a more patient-tailored approach in cancer treatment may be utilised;
- Address how the implementation of novel monitoring technologies for the surgeon may be utilised to open-up a risk-free window of opportunity for active surveillance; and
- Even if surgery is determined to be needed, what are the alternative interventions to preserve the quality of life in patients.
- Implement watch and wait protocols as a valid option for more patient-tailored cancer monitoring and treatment;
- Develop in vivo imaging methods and hybrid probes that allows for more accurate multimodal (optical, PET, MRI) visualisation of new tumour growth;
- Develop specialised assays based upon non-invasive liquid biopsies for active monitoring of patients; and
- Implementation of novel approaches for localised therapy.
- A consensus for full implementation of watch and wait for different cancers involving shared databases, training facilities and determine best practices for patient management;
- Beyond state of art technologies, including camera systems, hardware and liquid biopsies, that will allow better prognosis and management of patients; and
- Improved methods for the localised (as opposed to systemic) delivery of immunotherapy or radiotherapy.